CSX said it expects revenue to fall as much as 2% in 2019, well below a previous forecast of an increase of 1% to 2%.Marketsread more
Challenging conditions in the U.S. housing market, along with tighter currency controls by the Chinese government, cause a stunning drop in foreign demand for American homes.Real Estateread more
The growth in net interest income, a main engine of the industry's profit, looks to slow to a halt in the back half of this year.Banksread more
His case for gold comes as central banks get more aggressive with policies that devalue currencies and are about to cause a "paradigm shift" in investing.Marketsread more
Amazon also said that on Monday and Tuesday it sold more Amazon devices — like the Echo Dot, the Fire TV Stick and Alexa Voice Remote — over a two-day period than it ever has...Retailread more
Here's how Amazon sells ads, and why it has a natural edge over Google and Facebook in some areas.Technologyread more
Facebook's head of Calibra David Marcus faced skepticism from lawmakers at a House Financial Services hearing on its digital currency plans.Technologyread more
During a speech on "Medicare for All," Bernie Sanders will urge 2020 Democratic candidates to reject money from health care industries.2020 Electionsread more
The "'Cadillac tax," set to go into effect in 2022, is unpopular with both Republicans and Democrats, who say it punishes the middle class.Health and Scienceread more
The news comes after eBay announced a strategic portfolio review on March 1.The Faber Reportread more
If the S&P 500 climbs another 4%, it will have doubled the peak reached in the previous bull market, Michael Santoli notes.Trading Nationread more
A drug designed to combat seizures in children with severe epilepsy has been approved by an outside panel of advisors to the FDA, a major milestone on the way to full approval.
Epidiolex would be the first drug derived from cannabis on the U.S. market.
The panel of 13 advisors concluded that the benefit-risk profile of Epidiolex is favorable for the treatment of seizures. Earlier this week, FDA staff indicated support for the drug in light of the results of clinical trials.
Shares of U.K.-based GW Pharmaceuticals, which makes Epidiolex, were up more than 1 percent following the news.
The medicine's active ingredient cannabidiol is derived from the cannabis plant. Epidiolex does not contain THC and does not give patients any psychoactive effects. The FDA has already approved synthetic cannabinoids to alleviate the side effects of treatments such as chemotherapy.
Industry watchers expect the eventual approval of Epidiolex will encourage further research and investment into cannabis-based drugs.
The FDA is expected to issue a final decision on June 27.
— Reuters contributed to this report.